特发性肺纤维化与结缔组织病相关间质性肺病的循环生物标志物:现状系统综述与荟萃分析
该研究系统检索MEDLINE和Embase 1960年1月至2019年2月文献,纳入70项研究(其中20项进入荟萃分析),评估循环生物标志物在IPF与CTD-ILD中的诊断与预后价值;发现KL-6和SP-D可诊断两者肺纤维化,KL-6诊断IPF的OR为520.95,CCL18对预后预测价值较高,但缺乏疾病特异性标志物,需纵向研究验证。
要点
- KL-6诊断IPF的OR为520.95,诊断CTD-ILD的OR为26.43,均为p<0.001。
- SP-D诊断IPF的OR为33.81(p=0.003),诊断SSc-ILD的OR为13.24。
- CCL18预测IPF预后OR为10.22,预测SSc预后OR为2.62,均p<0.001。
核心结论
- CTD-ILD与IPF共享部分循环生物标志物,提示共同病理生理通路,但缺乏疾病特异性标志物。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE和Embase数据库1960年1月至2019年2月文献,纳入70项研究,其中20项进入荟萃分析。
主要发现
- KL-6和SP-D可诊断IPF和CTD-ILD的肺纤维化,KL-6诊断价值最强(IPF OR 520.95[110.07-2465.58],p<0.001;CTD-ILD OR 26.43[7.15-97.68],p<0.001)。
- SP-D诊断IPF的OR为33.81[3.20-357.52](p=0.003),诊断SSc-ILD的OR为13.24[3.84-45.71]。
- MMP7对IPF诊断有意义(p<0.001),CCL18与SSc中ILD诊断相关。
- CCL18和KL-6均可预测ILD结局,CCL18预测价值更高(IPF OR 10.22[4.72-22.16],p<0.001;SSc OR 2.62[1.71-4.03],p<0.001)。
关键数值与推荐
- KL-6诊断IPF的OR为520.95(95%CI 110.07-2465.58,p<0.001),诊断CTD-ILD的OR为26.43(95%CI 7.15-97.68,p<0.001)。
- SP-D诊断IPF的OR为33.81(95%CI 3.20-357.52,p=0.003),诊断SSc-ILD的OR为13.24(95%CI 3.84-45.71)。
- CCL18预测IPF预后的OR为10.22(95%CI 4.72-22.16,p<0.001),预测SSc预后的OR为2.62(95%CI 1.71-4.03,p<0.001)。
临床怎么用
- KL-6和SP-D可作为IPF与CTD-ILD肺纤维化的诊断参考标志物。
- CCL18和KL-6可用于IPF与SSc-ILD的预后预测参考。
- 目前尚不能将潜在生物标志物常规转化至临床实践,需纵向研究验证。
局限性
- 缺乏疾病特异性生物标志物。
- 需大规模纵向研究验证后方可临床转化。
- 需进一步研究评估生物标志物对治疗反应的预测价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Interstitial lung diseases (ILDs) are complex diseases with various courses where personalized medicine is highly expected. Biomarkers are indicators of physiological, pathological processes or of pharmacological response to therapeutic interventions. They can be used for diagnosis, risk-stratification, prediction and monitoring of treatment response. To better delineate the input and pitfalls of biomarkers in ILDs, we performed a systematic review and meta-analysis of literature in MEDLINE and Embase databases from January 1960 to February 2019. We focused on circulating biomarkers as having the highest generalizability. Overall, 70 studies were included in the review and 20 studies could be included in the meta-analysis. This review highlights that ILD associated with connective tissue diseases (CTD-ILD) and idiopathic pulmonary fibrosis (IPF) share common biomarkers, suggesting common pathophysiological pathways. KL-6 and SP-D, could diagnose lung fibrosis in both IPF and CTD-ILD, with KL-6 having the strongest value (OR: 520.95[110.07-2465.58], p<0.001 in IPF and OR:26.43[7.15-97.68], p<0.001 in CTD-ILD), followed by SPD (OR: 33.81[3.20-357.52], p = 0.003 in IPF and 13.24 [3.84-45.71] in SSc-ILD), MMP7 appeared as interesting for IPF diagnosis (p<0.001), whereas in SSc, CCL18 was associated with ILD diagnosis. Both CCL18 and KL-6 were predictive for the outcomes of ILDs, with higher predictive values for CCL18 in both IPF (OR:10.22[4.72-22.16], p<0.001 and in SSc [2.62[1.71-4.03], p<0.001). However, disease specific biomarkers are lacking and large longitudinal studies are needed before the translational use of the potential biomarkers in clinical practice. With the recent availability of new effective therapies in ILDs, further studies should assess response to treatment.
引用
- Elhai M, Avouac J, Allanore Y, et al. Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: Where do we stand? Semin Arthritis Rheum. 2020. PMID: 32089354. doi:10.1016/j.semarthrit.2020.01.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。